OTCMLMDXF
Market cap156mUSD
Oct 25, Last price
0.01USD
Name
LumiraDx Ltd
Chart & Performance
P/E
—
P/S
0.61
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
254m
-39.62%
Net income
-449m
L+345.79%
CFO
-162m
L+20.18%
Profile
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||
Revenues | 254,476 -39.62% | 421,428 202.85% | ||
Cost of revenue | 431,408 | 530,629 | ||
Unusual Expense (Income) | ||||
NOPBT | (176,932) | (109,201) | ||
NOPBT Margin | ||||
Operating Taxes | 7,804 | 2,844 | ||
Tax Rate | ||||
NOPAT | (184,736) | (112,045) | ||
Net income | (449,195) 345.79% | (100,764) -58.19% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 97,998 | 54,724 | ||
BB yield | -38.58% | -3.76% | ||
| Debt | ||||
Debt current | 9,225 | 5,773 | ||
Long-term debt | 423,477 | 361,406 | ||
Deferred revenue | 15,769 | 20,992 | ||
Other long-term liabilities | 57,805 | (10,585) | ||
Net debt | 321,271 | 235,034 | ||
| Cash flow | ||||
Cash from operating activities | (162,107) | (134,883) | ||
CAPEX | (24,983) | (106,346) | ||
Cash from investing activities | (24,983) | (106,346) | ||
Cash from financing activities | 165,289 | 219,167 | ||
FCF | 10,928 | (400,887) | ||
| Balance | ||||
Cash | 100,010 | 132,145 | ||
Long term investments | 11,421 | |||
Excess cash | 98,707 | 111,074 | ||
Stockholders' equity | (112,102) | 162,600 | ||
Invested Capital | 474,824 | 398,062 | ||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 282,242 | 163,256 | ||
Price | 0.90 -89.90% | 8.91 | ||
Market cap | 254,018 -82.54% | 1,454,609 | ||
EV | 575,022 | 1,689,463 | ||
EBITDA | (143,645) | (83,487) | ||
EV/EBITDA | ||||
Interest | 134,563 | 117,943 | ||
Interest/NOPBT | ||||